Eli Lilly and Company (LLY)
Lilly's Chief Scientific Officer has big plans for the next generation of weight loss drugs
Eli Lilly's Chief Scientific Officer Dan Skovronsky says the company wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in obesity.
From pills to new uses, here's what Eli Lilly's top scientist sees as the future of weight loss drugs
Eli Lilly Chief Scientific Officer Dan Skovronsky said newer obesity medicines need to deliver more than just weight loss to compete with Zepbound and Wegovy. The development of pills and more potent drugs are two areas where Lilly is focusing.
3 Stocks That Could Trounce the Market in 2025
If you're content with market-level returns, investing in an exchange-traded fund (ETF) is the way to go. But if not, you'll need to find stocks that hold the potential to pack more punch.
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
Investors should never ignore valuations when picking stocks. The price a stock trades at can drastically impact your overall returns.
LLY Rises More Than 4% in a Week: How to Play the Stock
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Will Eli Lilly Stock Keep Climbing? Q2 Trial Results Are Crucial
Eli Lilly and Company NYSE: LLY is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the stock market and healthcare system. Shares have performed well in 2025, with a total return of 12% as of the Feb. 11 close.
My 3 Top Picks for Stocks That Could Double Over the Next 3 Years
Finding stocks with the potential to double in just three years is no easy feat, even in this bull market.
Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
2 Growth Stocks to Buy Hand Over Fist in February
Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in other industries -- even in healthcare, a sector some investors might consider boring.
Buy, Sell, Or Hold LLY Stock At $870?
Eli Lilly (NYSE: LLY) fourth-quarter performance exceeded the street expectations, with the company delivering adjusted earnings of $5.32 per share versus the projected $4.95. Revenue came in at $13.5 billion, slightly below the consensus estimate of $13.6 billion.
Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant
David Risinger, Leerink Partners, joins 'Fast Money' to talk Eli Lilly earnings.
Eli Lilly Q4 Earnings: Now The Magical $1 Trillion Dollar Market Cap Is In Sight
Eli Lilly and Company's Q4 and full-year earnings showcased impressive growth, driven by tirzepatide's success, leading to a 45% revenue increase in Q4 and 32% for the year. Tirzepatide, marketed as Mounjaro for Type 2 Diabetes and Zepbound for Obesity, has significantly outperformed competitors, contributing to over 37% of Lilly's revenues. Lilly's diverse portfolio, including cardiometabolic, oncology, and immunology divisions, also showed strong growth, with significant investments in manufacturing to address supply concerns.
